Unknown PHASE3 INTERVENTIONAL 2-arm NCT04979221

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Sponsor: Hospital de Clinicas de Porto Alegre

Updated 4 times since 2021 Last updated: Jul 27, 2021 Started: Jul 26, 2021 Primary completion: Jan 26, 2022 Completion: Feb 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on COVID-19 Pneumonia, this trial is ongoing. The trial is conducted by Hospital de Clinicas de Porto Alegre and has accumulated 4 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Recruiting PHASE3

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital de Clinicas de Porto Alegre

Data source: Hospital de Clinicas de Porto Alegre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Porto Alegre, Brazil